Search and Hit Enter

Russia has started production of Sputnik V – world’s FIRST registered Covid-19 vaccine

Russia has begun production of the novel coronavirus vaccine developed by the N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, the Russian Health Ministry’s press service told reporters on Saturday.

“The production of the vaccine against the novel coronavirus COVID-19, developed by the N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, has begun,” the message says.

On August 11, Russia became the first country to register a coronavirus vaccine, which was named Sputnik V. Russian Health Minister Mikhail Murashko informed that the vaccine created by the N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology had shown its effectiveness and safety on the outcomes of clinical trials. It was created on a platform that had been used for the development of a number of other vaccines.

According to the Russian Health Ministry, experience shows that such vaccines are capable of developing long-term immunity that lasts for up to two years. Head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev pointed out that Russia had received applications for more than 1 bln doses of the vaccine from 20 countries.

The new Russian coronavirus vaccine known as Sputnik V. © Sputnik / Russian Health Ministry

The formula, officially known as ‘Gam-COVID-Vak,’ was developed by the Gamaleya National Research Center in the Russian capital. It has two components that need to be injected three weeks apart to trigger an immune response to Covid-19.

The director of Russia’s sovereign wealth fund, which bankrolled the project, Kirill Dmitriev pointed out that Moscow had received applications for more than one billion doses of the vaccine from 20 countries.

Russia’s health regulator registered the vaccine after it passed Phase II trials in June and July. It was decided that completing a Phase III trial was not necessary for the initial roll-out because it is based on an already proven platform. However, it’s important to note that Sputnik V won’t go into general circulation until January 2021, allowing another four to five months in which to further observe its effectiveness.

The decision was criticized by some Western governments and health professionals, who consider it rushed and potentially dangerous. That said, some of them seemed to be under the impression that the vaccine was going into immediate mass circulation. In reality, it will initially only be available to vulnerable workers in important frontline roles. Even then, participation is voluntary, with nobody forced to take part.

Russian Health Minister Mikhail Murashko said, earlier this week, during a meeting with President Vladimir Putin that medical workers and teachers would be the first to get the vaccine. The Health Ministry added that the data from the trials will soon be published and this will hopefully alleviate some of the concerns surrounding it.

President Putin announced the registration of Sputnik V on Tuesday.

The head of the Gamaleya Center, Alexander Gintsburg, explained that three companies are preparing to produce the formula, adding that it would first be supplied to 10-15 regions of the country, however, he did not specify where exactly.

Gintsburg warned that it may take up to a year for all Russians to get full access to the vaccine. “It is important to understand when we will be able to meet the demand of the country. I hope that it will happen within 9-12 months,” he told Russia’s TASS news agency.

He added that in about a month, around one million vaccine doses would be produced at the three plants mentioned. “By the end of the year, there will be 1.5-2 million doses produced. These are tangible and good numbers,” he said.


MOSCOW, RUSSIA – AUGUST 6, 2020: Ampoules contain a vaccine for COVID-19 developed by Gamaleya Research Institute of Epidemiology and Microbiology under the Russian Healthcare Ministry. A two-component adenoviral vector-based vaccine, Gam-COVID-Vak will be available to public on January 1, 2021. Russian Direct Investment Fund and Gamaleya Research Center/TASS


Source: RT and TASS